The Ludwig Program for the Study of Neuroimmune Interactions in Dementia is led by co-directors Stephen Strittmatter, MD, PhD, Vincent Coates Professor of Neurology and chair and professor of neuroscience; director of the Kavli Institute for Neuroscience; director of Cellular Neuroscience, Neurodegeneration & Repair; director of the Memory Disorders Clinic; and director of the Yale Alzheimer's Disease Research Center; and Lauren Sansing, MD, professor of neurology and of immunobiology, and vice chair in the Department of Neurology for Academic and Faculty Affairs.
Today, there are more than 55 million people worldwide living with dementia, seven million of whom are in the U.S. As of 2020, Alzheimer’s disease accounted for 60% to 80% of cases. There are currently no cures for Alzheimer’s or related disorders, and the urgency to develop effective treatments only grows. It is estimated that by 2050, Alzheimer’s will affect nearly 14 million people in the U.S. alone.
“Our goal is to accelerate research at the intersection of neuroinflammation and Alzheimer’s disease," said Carol Ludwig, who is president of the LFF. “Under Dr. Strittmatter's and Dr. Sansing's expert leadership, we hope the program will foster a vibrant community of Yale's accomplished faculty for groundbreaking research in this emerging field, ultimately developing novel diagnostics and therapeutics for this devastating disease.”